Urology News and Research

Latest Urology News and Research

DiagnoCure's proprietary prostate cancer biomarker PCA3 presented at 2010 EAU meeting

DiagnoCure, Inc., a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced that its proprietary prostate cancer biomarker PCA3 was the topic of over 13 presentations at the 2010 European Association of Urology meeting, the world largest urology event, held in Barcelona, Spain, with 14,000 registrants.

22 Apr 2010

Gen-Probe's PROGENSA PCA3 assay helps determine necessity of initial biopsy in prostate cancer suspect men

Gen-Probe's PROGENSA® PCA3 assay can help predict the outcome of initial prostate biopsies in men suspected of having prostate cancer, according to a study of the molecular urine test presented in a scientific poster last week at the 25th annual European Association of Urology (EAU) Congress in Barcelona, Spain.

22 Apr 2010

Seattle Genetics, Agensys present ASG-5ME ADC preclinical data at 101st AACR

Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today reported preclinical data with ASG-5ME, an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors. In models of human prostate and pancreatic cancer, ASG-5ME was found to have potent and long lasting antitumor activity. The findings were presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held in Washington, D.C.

22 Apr 2010

New treatment modalities for RCC

Renal cell carcinoma accounts for about 3% of all solid tumours in adults, and worldwide, more than 200.000 new cases and 100.000 deaths result each year from this malignancy.

21 Apr 2010

IMPACT trial shows improvement in OS for metastatic CRPC

Dr. Neal Shore (GB) presented for the first time in Europe the updated results of the study "Sipuleucel-T Active Cellular Immunotherapy for Metastatic, Castration-Resistant Prostate Cancer: results from the IMPACT trial," during the second plenary session of the 25th Anniversary EAU Congress in Barcelona.

21 Apr 2010

New report studies healthcare market in Europe and provides insights, analysis up to 2014

Healthcare has always been an area of utmost importance. It has significant economic relevance and has been allocated a higher percent of gross domestic product in many countries compared to most other sectors such as transport and communication, construction and education. Healthcare also has a huge impact on employment, for the fact that most related activities are provided by people.

20 Apr 2010

Meat cooked at high temperatures increases risk of developing bladder cancer

People who eat meat frequently, especially meat that is well done or cooked at high temperatures, may have a higher chance of developing bladder cancer, according to a large study at The University of Texas M. D. Anderson Cancer Center presented at the American Association for Cancer Research 101st Annual Meeting 2010. This risk appears to increase in people with certain genetic variants.

20 Apr 2010

Caliper Life Sciences introduces Quantum FX stand-alone microCT system for preclinical imaging

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery, life sciences research and molecular diagnostics, today announced the Quantum FX, a stand-alone microCT system for preclinical imaging. Introduced at the American Association for Cancer Research Annual Meeting 2010, the Quantum FX is a low dose, microCT system that provides researchers with a 3-dimensional anatomical view of disease activity, tumor development and therapeutic response over multiple time points during the course of a study.

19 Apr 2010

FDA approves Sagent Pharmaceuticals' mesna injection for hemorrhagic cystitis

Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced the Company has received U.S. Food and Drug Administration (FDA) approval to market mesna injection (mesna), a prophylactic agent used to reduce the incidence of hemorrhagic cystitis caused by ifosfamide chemotherapy.

19 Apr 2010

EORTC 30904 study: Conservative surgery not inferior to radical renal surgery

The latest results from the European Organisation for Research and Treatment of Cancer (EORTC) 30904 study were presented in a plenary session today at the Anniversary European Association of Urology Congress in Barcelona, which showed that conservative surgery is not inferior to radical renal surgery or nephrectomy.

19 Apr 2010

EAU publishes live webcasts of sessions from 25th Anniversary EAU Congress

The Anniversary EAU Congress started successfully yesterday, although the force majeure circumstances - the eruption of a volcano in Iceland - which shut down many North-European airports, made changes in the programme necessary. To accomodate all urologists, health professionals, media representatives etc who have been stranded due to the volcanic eruption in Iceland, the EAU is publishing live webcasts of the sessions from the 25th Anniversary EAU Congress.

19 Apr 2010

Debate continues over prostate cancer screening in Europe

The European Association of Urology reiterated that it does not recommend a mass screening policy in Europe for men who are concerned over prostate cancer, a stance which reflects the position it issued last year regarding prostate cancer screening. "We don't believe that the time has come for mass screening," said EAU Secretary General.

19 Apr 2010

Results from Phase 2 study of BOTOX in IOAB patients presented at Anniversary EAU Congress

Treatment options for idiopathic OAB patients not adequately managed by anticholinergic therapy are limited; either highly invasive, expensive or of limited efficacy. BOTOX® (onabotulinumtoxinA) may provide a minimally invasive effective treatment. Professor Chris Chapple and his group conducted the first large, double-blind, placebo-controlled, dose ranging study to systematically asses the benefit/risk balance of the use of BOTOX® in IOAB across a wide range of doses.

19 Apr 2010

EAU honours urological experts at 25th Anniversary Congress

On 16 April 2010 the European Association of Urology opened its 25th Anniversary Congress. During the ceremony, several urological experts were honoured with awards for the outstanding work they did for the urological community. EAU Secretary General Per-Anders Abrahamsson handed them out.

17 Apr 2010

EAU launches new website

The EAU recently launched its new website. Online efforts are continued under the same name: www.uroweb.org. But everything else has been redesigned in line with the latest internet trends - user-friendliness, interactivity, elegance. Prof. Manfred Wirth, EAU Executive Member Communication, says: "The EAU is a dynamic organisation.

17 Apr 2010

Updated clinical guidelines presented at EAU Anniversary Congress

A number of updated guidelines are presented at the Anniversary Congress of the European Association of Urology (EAU) held in Barcelona, from 16 through 20 April. The abridged versions - Pocket Guidelines - which are based on the extended text documents will also be available in Barcelona to all EAU members and press.

17 Apr 2010

Watson Laboratories' ANDA for generic Toprol XL tablets receives FDA approval

Watson Pharmaceuticals, Inc., today announced that its subsidiary, Watson Laboratories, Inc. - Florida, has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application for metoprolol succinate extended-release tablets USP in the 100 and 200 mg strengths, the generic equivalent to AstraZeneca's Toprol XL® tablets.

16 Apr 2010

Stress hormones may suppress tumor growth: Study

Chronic stress triggers a chain of molecular events that protects breakaway ovarian cancer cells from destruction, a team of researchers led by scientists at The University of Texas M. D. Anderson Cancer Center reports April 12 in the early online publication of the Journal of Clinical Investigation.

13 Apr 2010

Lockheed Martin pledges $4M to aid UCLA Health System's Operation Mend program

The Lockheed Martin Corp. announced today a pledge of $4 million to benefit the UCLA Health System's Operation Mend program, which provides reconstructive surgeries and other health care needs to U.S. military personnel wounded in Iraq and Afghanistan.

13 Apr 2010

EDAP's Sonolith i-move lithotripter receives European approval

EDAP TMS SA, the global leader in therapeutic ultrasound, announced today the European approval of its new lithotripter, the Sonolith i-move. The EDAP sales team and distributors will begin marketing Sonolith i-move immediately and will officially introduce the product to distributors, partners and visiting urologists at the European Association Urology (EAU) congress, Booth #14, from April 17-19, 2010 in Barcelona, Spain.

12 Apr 2010